Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
← catalyst calendarSponsored by Merit Medical Systems, Inc. (industry) · MMSI — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
100estimated
Sites
4
Countries
Australia, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-22 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Uterine Fibroid
Intervention
- Device: Bearing nsPVA
Primary outcomes
what the primary-completion date above is the date OFPrimary Safety
measured 30 days
Primary Effectiveness
measured 6 months
Permalink · MMSI's whole pipeline · Catalyst calendar · Every registered study · What changed